Venture Capital Pulse — April 13, 2026

---

Top Deals This Week

---

SiFive — $400M (Round Type Undisclosed)

• Sector: Semiconductors / Custom Chip Design
• Lead investor(s): Undisclosed
• What they do: SiFive designs custom RISC-V processor IP and chips for enterprise and defense clients
• Why it matters: The round signals continued investor conviction in custom silicon as an alternative to commodity chip designs — a direct play on AI inference and edge compute demand where off-the-shelf GPUs are too expensive or inflexible

---

Life Bio — $80M Series (Undisclosed)

• Sector: Biopharma / Longevity
• Lead investor(s): Undisclosed
• What they do: Longevity biotech targeting biological aging mechanisms
• Why it matters: One of the larger biotech rounds tracked this week by the Fierce Biotech Fundraising Tracker (which records rounds of $50M+), signaling continued institutional appetite for longevity science even as deal counts compress

---

Vivatides — $54M Series A

• Sector: Biopharma
• Lead investor(s): Undisclosed
• What they do: Early-stage biotech pursuing novel therapeutic mechanisms (series A stage)
• Why it matters: A Series A at $54M reflects the ongoing "megadeal" trend even at early stages — a structural shift Crunchbase has been tracking where seed and Series A rounds are increasingly oversized relative to historical norms

---

AfterQuery — Undisclosed Round

• Sector: AI Infrastructure / GPU Cloud
• Lead investor(s): Undisclosed
• What they do: AI-focused infrastructure company (GPU cloud / data platform)
• Why it matters: Featured in TechStartups' April 9 roundup as part of a broader "infrastructure-first investing" shift, with capital flowing heavily into AI chips, GPU cloud platforms, and carbon-negative fuels

---

New Funds & LP Moves

• Zero Shot (OpenAI Alumni Fund): A new VC fund with deep ties to OpenAI is quietly targeting a $100M first close. The firm has already written some checks. The fund's founders have backgrounds at OpenAI and are focused on early-stage AI bets. The $100M target is described as a "potentially" figure — the final close size could be larger. This move reflects a well-established pattern of frontier AI lab alumni spinning out to back the next generation of AI-native companies.

• South Korea $1.3B Secondary Fund: South Korea's brokerage firms and related institutions are mulling the launch of a 2-trillion-won (~$1.3 billion) secondary fund, as domestic VC firms struggle with exit bottlenecks. The move reflects a global trend: secondary markets are increasingly being used as a pressure valve as the primary exit market (IPOs, M&A) remains constrained.

---

Exits & Acquisitions

• Exit market contraction (Q1 2026): CB Insights' "State of Venture Q1'26" report (published April 7, 2026) confirmed that while quarterly funding hit a record $286B, exits declined to a two-year low. The global investor market is also shrinking in terms of active participants. This is the defining tension of the current VC cycle: record capital deployment with near-frozen liquidity.

• M&A as primary exit channel: Law firm Foley & Lardner's April 2026 analysis of Q1 data noted that "M&A is the active exit market" as public software multiples remain well below historical averages and traditional SaaS faces structural pressure. With the IPO window largely closed for most venture-backed companies, strategic acquirers are the dominant liquidity source — but deal volume remains uneven.

---

Sector Spotlight: Semiconductors, Biotech, and AI Infrastructure

This week's largest deals cut across semiconductors, biotech, and AI infrastructure — but the common thread is hardware and deep tech, not software.

SiFive's $400M round led the week's deal list and puts custom chip design back in the spotlight. The round follows months of investor focus on AI inference efficiency, where standard GPUs are increasingly seen as too costly or energy-intensive for edge deployment. RISC-V-based custom silicon represents a structural alternative, and SiFive is the clearest pure-play bet on that thesis.

Biotech posted multiple $50M+ rounds this week per the Fierce Biotech Fundraising Tracker, with Life Bio ($80M) and Vivatides ($54M Series A) among the notables. Deal count in biopharma is actually declining even as dollar amounts rise — a compression dynamic mirroring the broader VC market.

AI Infrastructure (GPU cloud, data platforms) rounded out the week, with the April 9 TechStartups roundup highlighting a clear pivot toward "infrastructure-first investing." Founders building the picks-and-shovels of the AI economy — chips, cloud platforms, energy-efficient compute — are commanding the most attention.

What this signals: The market is moving away from pure software plays toward capital-intensive, hardware-adjacent sectors. Investors who were burned by bloated SaaS valuations in 2021–2022 are now explicitly rewarding founders who can show defensible IP in silicon, biology, or physical infrastructure. For founders, this means the bar for software-only pitches is higher than ever, while hardware and biotech deals are flowing at pre-revenue valuations not seen since 2021.

---

What to Watch Next Week

• European Venture Debt Dynamics: PitchBook's April 11 analysis found that AI mega-deals are driving European venture debt volumes, but deal count is shrinking — a sign that debt capital is concentrating in fewer, larger bets. Watch for follow-on data on whether rate hike pressures and cautious LPs begin to curb this trend.

• Zero Shot Fund Close: OpenAI alumni fund Zero Shot is actively deploying capital from its first fund. Any formal close announcement or lead LP disclosure would be a significant signal for the AI-focused early-stage market.

• South Korea Secondary Fund Decision: A potential $1.3B secondary fund launch by South Korean institutions could set a regional precedent for secondary market infrastructure and provide a blueprint other emerging VC ecosystems may follow.

• SPAC Market Revival: PitchBook flagged (April 10) an uptick in SPAC activity from hot-sector companies. If SPAC deal flow accelerates, it could provide an alternative exit route for mid-stage AI and defense tech companies — particularly relevant given the two-year low in traditional exit volumes confirmed by CB Insights.